{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:17:24Z","timestamp":1786997844916,"version":"build-2736575974"},"reference-count":74,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.vaccine.2020.10.089","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T01:17:59Z","timestamp":1606526279000},"page":"438-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France"],"prefix":"10.1016","volume":"39","author":[{"given":"Laureen","family":"Majed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bresse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"El Mouaddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-7231","authenticated-orcid":false,"given":"Vincent J.","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pavelyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Levy-Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-8036","authenticated-orcid":false,"given":"Elamin","family":"Elbasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.10.089_b0005","unstructured":"Genital HPV Infection - Fact Sheet. 2015 02\/23\/2015 [cited 2015 08\/06\/2015]; Available from: http:\/\/www.cdc.gov\/std\/hpv\/stdfact-hpv.htm"},{"key":"10.1016\/j.vaccine.2020.10.089_b0010","unstructured":"Centers for Disease Control and Prevention. How Many Cancers Are Linked with HPV Each Year? 2018 13\/12\/2018]; Available from: https:\/\/www.cdc.gov\/cancer\/hpv\/statistics\/cases.htm."},{"key":"10.1016\/j.vaccine.2020.10.089_b0015","unstructured":"WHO. Human papillomavirus (HPV) and cervical cancer. 2019; Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs380\/en\/."},{"key":"10.1016\/j.vaccine.2020.10.089_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13027-017-0129-6","article-title":"Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe","volume":"12","author":"Hartwig","year":"2017","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.vaccine.2020.10.089_b0025","article-title":"Extrait des mises \u00e0 jour en gyn\u00e9cologie m\u00e9dicale \u2013","author":"CNOGF","year":"2007","journal-title":"Condylomes g\u00e9nitaux."},{"key":"10.1016\/j.vaccine.2020.10.089_b0030","unstructured":"INCa, Les cancers en France - Edition 2017. 2017."},{"key":"10.1016\/j.vaccine.2020.10.089_b0035","series-title":"Projection de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine en 2017","author":"J\u00e9hannin-Ligier","year":"2017"},{"key":"10.1016\/j.vaccine.2020.10.089_b0040","unstructured":"C\u00e9piDC, Effectifs de d\u00e9c\u00e8s pour le code CIM 21 et l'ann\u00e9e 2015. 2015."},{"issue":"3","key":"10.1016\/j.vaccine.2020.10.089_b0045","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10654-017-0334-z","article-title":"New cancer cases in France in 2015 attributable to infectious agents: a systematic review and meta-analysis","volume":"33","author":"Shield","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2020.10.089_b0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2407-12-30","article-title":"Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review","volume":"12","author":"Hartwig","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vaccine.2020.10.089_b0055","unstructured":"St\u00e8ve consultants, Description du fardeau des infections d\u00fbes aux HPV - Rapport d'\u00e9tude Partie I - L\u00e9sions pr\u00e9cancereuses du col de l'ut\u00e9rus. . 2016."},{"key":"10.1016\/j.vaccine.2020.10.089_b0060","unstructured":"St\u00e8ve consultants, Description du fardeau des infections d\u00fbes aux HPV - Rapport d'\u00e9tude Partie II - Cancers ano-g\u00e9nitaux et des voies a\u00e9ro-digestives sup\u00e9rieures. 2016."},{"key":"10.1016\/j.vaccine.2020.10.089_b0065","doi-asserted-by":"crossref","unstructured":"C\u00e9piDC, Effectifs de d\u00e9c\u00e8s pour le code CIM 51 et l'ann\u00e9e 2015. 2015.","DOI":"10.1016\/S1773-035X(15)30074-5"},{"key":"10.1016\/j.vaccine.2020.10.089_b0070","unstructured":"C\u00e9piDC, Effectifs de d\u00e9c\u00e8s pour le code CIM 52 et l'ann\u00e9e 2015. 2015."},{"key":"10.1016\/j.vaccine.2020.10.089_b0075","unstructured":"SNFCP. Les condylomes de l'anus. 2013; Available from: https:\/\/www.snfcp.org\/informations-maladies\/infections-sexuellement-transmises\/condylomes-de-lanus\/."},{"issue":"9","key":"10.1016\/j.vaccine.2020.10.089_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202564","article-title":"Epidemiological and economic burden of potentially HPV-related cancers in France","volume":"13","author":"Abramowitz","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.10.089_b0085","unstructured":"Plan Cancer 2014-2019. F\u00e9vrier 2012."},{"key":"10.1016\/j.vaccine.2020.10.089_b0090","unstructured":"Institut national du cancer, D\u00e9pistage du cancer du col de l'ut\u00e9rus. 2018."},{"key":"10.1016\/j.vaccine.2020.10.089_b0095","unstructured":"Introduction of HPV vaccines in European Union countries - an update. 2015, European Centre for Disease Prevention and Control."},{"key":"10.1016\/j.vaccine.2020.10.089_b0100","unstructured":"European Medicine Agency. Cervarix - EPAR summary for the public. 2016; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000721\/WC500024634.pdf."},{"key":"10.1016\/j.vaccine.2020.10.089_b0105","unstructured":"European Medicine Agency - Committee for Medicinal Products for Human Use, Gardasil human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) - Summary of opinion. 2010."},{"key":"10.1016\/j.vaccine.2020.10.089_b0110","unstructured":"European Medicines Agency, Gardasil 9 - Summary of product characteristics. 2016."},{"key":"10.1016\/j.vaccine.2020.10.089_b0115","unstructured":"European Medicines Agency, Gardasil 9 - EPAR summary for the public. 2016."},{"key":"10.1016\/j.vaccine.2020.10.089_b0120","unstructured":"Haut Conseil de la Sant\u00e9 Publique, Avis relatif \u00e0 la place du vaccin GARDASIL 9\u00ae dans la strat\u00e9gie actuelle de pr\u00e9vention des infections \u00e0 papillomavirus humains 2017."},{"key":"10.1016\/j.vaccine.2020.10.089_b0125","unstructured":"Haute autorit\u00e9 de sant\u00e9, Recommandation vaccinale - Elargissement de la vaccination contre les papillomavirus aux gar\u00e7ons. 2019."},{"key":"10.1016\/j.vaccine.2020.10.089_b0130","unstructured":"Public S\u00e9nat, La recommandation du vaccin anti-HPV \u00e9tendue aux gar\u00e7ons dans deux r\u00e9gions. 2018."},{"issue":"8","key":"10.1016\/j.vaccine.2020.10.089_b0135","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1471-0528.2008.01743.x","article-title":"The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) in the UK","volume":"115","author":"Dasbach","year":"2008","journal-title":"BJOG"},{"issue":"5","key":"10.1016\/j.vaccine.2020.10.089_b0140","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1586\/14737167.8.5.491","article-title":"Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model","volume":"8","author":"Dasbach","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"42","key":"10.1016\/j.vaccine.2020.10.089_b0145","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.089_b0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg. Infect. Dis."},{"issue":"12","key":"10.1016\/j.vaccine.2020.10.089_b0155","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/MLR.0b013e318269e06d","article-title":"Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: the BEST study","volume":"50","author":"Favato","year":"2012","journal-title":"Med Care"},{"key":"10.1016\/j.vaccine.2020.10.089_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2015.08.010","article-title":"Cost-effectiveness analysis of universal human papillomavirus vaccination using a dynamic Bayesian methodology: the BEST II study","author":"Haeussler","year":"2015","journal-title":"Value in Health"},{"issue":"7","key":"10.1016\/j.vaccine.2020.10.089_b0165","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.4161\/hv.28834","article-title":"Projected impact of Cervarix(R) vaccination on oncogenic human papillomavirus infection and cervical cancer in the United Kingdom","volume":"10","author":"Van Effelterre","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"10.1016\/j.vaccine.2020.10.089_b0170","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.089_b0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1017\/S0266462307080026","article-title":"Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France","volume":"24","author":"Bergeron","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.089_b0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00038-010-0216-6","article-title":"A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer","volume":"56","author":"Demarteau","year":"2011","journal-title":"Int J Public Health"},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.089_b0185","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4161\/hv.22994","article-title":"A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France","volume":"9","author":"Bresse","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.10.089_b0190","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12879-016-1483-5","article-title":"Estimating the cost-effectiveness profile of a universal vaccination programme with a 9-valent HPV vaccine in Austria","volume":"16","author":"Boiron","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"42","key":"10.1016\/j.vaccine.2020.10.089_b0195","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"An Integrated Economic evaluation and HPV disease transmission models - Technical report accompanying the Manuscript \u201cImpact of vaccinating Boys and Men against HPV in the Inited States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.089_b0200","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Supplementary Online Appendix: A Technical Report Accompanying Manuscript: Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg. Infect. Dis."},{"issue":"1","key":"10.1016\/j.vaccine.2020.10.089_b0205","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/14737167.2016.1208087","article-title":"An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany","volume":"17","author":"Largeron","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.vaccine.2020.10.089_b0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12962-017-0073-8","article-title":"Cost-effectiveness analysis of the 9-valent HPV vaccine in Italy","volume":"15","author":"Mennini","year":"2017","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.vaccine.2020.10.089_b0215","unstructured":"Eurocare Survival of cancer patient in Europe. 2015, Istituto Nazionale Tumori Istituto Superiore di Sanit\u00e0."},{"key":"10.1016\/j.vaccine.2020.10.089_b0220","unstructured":"Cancer Research UK, Cervical cancer survival statistics. 2014."},{"key":"10.1016\/j.vaccine.2020.10.089_b0225","unstructured":"Donn\u00e9es Papillomavirus humains (HPV), Couverture vaccinale (%) par le vaccin HPV chez les jeunes filles pour une et trois doses: Institut de Veille Sanitaire. 2016."},{"key":"10.1016\/j.vaccine.2020.10.089_b0230","unstructured":"Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9, Calendrier des vaccinations et recommandations vaccinales. 2018."},{"key":"10.1016\/j.vaccine.2020.10.089_b0235","unstructured":"(INVS), F.N.I.f.H.S. Human Papillomavirus : HPV vaccination coverage in young girls in France. 2018 12\/12\/18]; Available from: http:\/\/invs.santepubliquefrance.fr\/Dossiers-thematiques\/Maladies-infectieuses\/Maladies-a-prevention-vaccinale\/Couverture-vaccinale\/Donnees\/Papillomavirus-humains."},{"issue":"9576","key":"10.1016\/j.vaccine.2020.10.089_b0240","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","author":"Ault","year":"2007","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.vaccine.2020.10.089_b0245","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2020.10.089_b0250","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2020.10.089_b0255","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"issue":"9574","key":"10.1016\/j.vaccine.2020.10.089_b0260","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.vaccine.2020.10.089_b0265","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.10.089_b0270","unstructured":"French National Authority for Health (HAS), [Methodological choices for the economic evaluation at HAS]. 2011"},{"key":"10.1016\/j.vaccine.2020.10.089_b0275","doi-asserted-by":"crossref","unstructured":"Szende A, J.B., Cabases J, Self-reported population health: An international perspective on EQ-5D. 2014.","DOI":"10.1007\/978-94-007-7596-1"},{"key":"10.1016\/j.vaccine.2020.10.089_b0280","unstructured":"C\u00e9piDC. Interrogation des donn\u00e9es sur les causes de d\u00e9c\u00e8s en 2013. 2013 20\/04\/2016]; Available from: http:\/\/www.cepidc.inserm.fr\/cgi\/broker.exe."},{"key":"10.1016\/j.vaccine.2020.10.089_b0285","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pvr.2015.06.003","volume":"1","author":"Hartwig","year":"2015","journal-title":"Papillomavirus Research"},{"key":"10.1016\/j.vaccine.2020.10.089_b0290","unstructured":"INCa, Les cancers en France - Edition 2015. 2016"},{"issue":"2","key":"10.1016\/j.vaccine.2020.10.089_b0295","first-page":"107","article-title":"Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France","volume":"35","author":"Monsonego","year":"2007","journal-title":"Gynecol Obstet Fertil"},{"key":"10.1016\/j.vaccine.2020.10.089_b0300","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12889-015-1779-1","article-title":"Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France","volume":"15","author":"Riethmuller","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2020.10.089_b0305","unstructured":"Haute autorit\u00e9 de sant\u00e9, Avis d'efficience - Gardasil\u00ae9. 2017"},{"key":"10.1016\/j.vaccine.2020.10.089_b0310","unstructured":"Bank, W. GDP per capita, PPP in France in 2017. 2019 27032019]."},{"key":"10.1016\/j.vaccine.2020.10.089_b0315","unstructured":"WHO. Choosing interventions that are cost-effective (CHOICE) project. 2004; Available from: https:\/\/www.who.int\/choice\/cost-effectiveness\/en\/."},{"key":"10.1016\/j.vaccine.2020.10.089_b0320","unstructured":"INVS. Human Papillomavirus : HPV vaccination coverage in young girls in France. 2018."},{"key":"10.1016\/j.vaccine.2020.10.089_b0325","unstructured":"Elbasha, E.H., An integrated economic evaluation and HPV disease transmission models technical report 2010."},{"issue":"4","key":"10.1016\/j.vaccine.2020.10.089_b0330","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.10.089_b0335","unstructured":"Brisson, M., Incremental Cost-Effectiveness of the 9-valent vs. the 4-valent HPV vaccine in the U.S., in: Advisory Committee on Immunization Practices (ACIP) meeting. 2014: Atlanta."},{"key":"10.1016\/j.vaccine.2020.10.089_b0340","unstructured":"Chesson, H., Overview of cost-effectiveness of 9-valent HPV vaccination, in: Advisory Committee on Immunization Practices. 2015: Atlanta."},{"key":"10.1016\/j.vaccine.2020.10.089_b0345","unstructured":"Weiss, T.P., M.; Dasbach, Potential health and economic impact of the investigational 9-valent HPV vaccine in the United States, in: International Papillomavirus Conference. 2014: Seattle."},{"key":"10.1016\/j.vaccine.2020.10.089_b0350","unstructured":"Health Information and Quality Authority. Health technology assessment of extending the national immunisation schedule to include HPV vaccination of boys 2018; Available from: https:\/\/www.hiqa.ie\/sites\/default\/files\/2018-12\/HTA-for-HPV-Vaccination-boys.pdf."},{"key":"10.1016\/j.vaccine.2020.10.089_b0355","unstructured":"(KCE), B.K.H.C., Cost-effectiveness analysis of HPV vaccination of boys in Belgium. 2018."},{"key":"10.1016\/j.vaccine.2020.10.089_b0360","unstructured":"Gov.uk, HPV vaccine to be given to boys in England. 2018."},{"key":"10.1016\/j.vaccine.2020.10.089_b0365","unstructured":"Department of Health and Social Care, Equality analysis : Human Papillomavirus (HPV) Vaccination. 2018."},{"issue":"9","key":"10.1016\/j.vaccine.2020.10.089_b0370","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/JOM.0b013e3181f12fb0","article-title":"The impact of precancerous cervical lesions on functioning at work and work productivity","volume":"52","author":"Lerner","year":"2010","journal-title":"J Occup Environ Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20314201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20314201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:52:27Z","timestamp":1759402347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20314201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0264410X20314201"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.089","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}